The cost-effectiveness of celecoxib versus non-steroidal anti-inflammatory drugs plus proton-pump inhibitors in the treatment of osteoarthritis in Saudi Arabia

Table 4 Cost effectiveness analysis over 6-month treatment duration: Base case analysis

Therapy	Cost/patient (US$)	QALYs gained/patient	ICER (ΔC/ΔE)	Comparator
Ibuprofen + PPI	1,314.50	0.34	3,866.18	No treatment
Celecoxib + PPI	1,422.80	0.40	1,805.00	Ibuprofen + PPI
Celecoxib*	1,543.50	0.37	Dominated	-
Diclofenac + PPI*	1,565.30	0.35	Dominated	-
Ibuprofen*	1,608.20	0.28	Dominated	-
Diclofenac*	1,695.00	0.31	Dominated	-
Etoricoxib + PPI	1,749.00	0.38	Dominated	-
Etoricoxib	1,839.10	0.36	Dominated	-

*Simple dominance: Another option is less expensive and more effective
ICER, incremental cost-effectiveness ratio; PPI, proton-pump inhibitor; QALY, quality-adjusted life year
ICER: additional cost per patient achieving a unit of effectiveness compared with the next less costly, non-dominated option

ISSN: 2191-1991